Celldex Therapeutics, Inc. (CLDX) Stock Analysis
A live, multi-source view of Celldex Therapeutics, Inc. (CLDX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Sector: Healthcare · Industry: Biotechnology · United States · 198 employees · celldex.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Celldex Therapeutics, Inc. (CLDX) had a market capitalization of $3.12B (forward -9.5) and a beta of 0.84; the shares traded in a 52-week range of $22.10 – $45.14 (68.2% over the year).
- Market cap
- $3.12B
- Enterprise value
- $2.40B
- Forward P/E
- -9.5
- Price / book
- 4.36
- EPS (trailing)
- $-4.35
- EPS (forward)
- $-4.16
- Payout ratio
- 0.0%
- 52-week range
- $22.10 – $45.14
- 52-week change
- 68.2%
- Beta
- 0.84
- Average volume
- 1.0M
- Shares outstanding
- 78.5M
- Short % of float
- 11.44%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Celldex Therapeutics, Inc. (CLDX) last closed at $39.68 (the last completed close before that scan).
Technicals at the scan: RSI 49 (neutral territory), price -3.4% versus its 20-day average, 20-day versus 50-day average spread +5.3%, MACD histogram -0.38.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 77/100.
Next scheduled company event: in 62 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for CLDX in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
CLDX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Celldex Therapeutics, Inc. (CLDX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell CLDX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.